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modifying antirheumatic drugs (tDMARDs) and are intolerant or contraindicated 
to methotrexate (MTX). Methods: A patient-level simulation model was applied 
to project lifetime costs and outcomes for 10.000 patients from a payer’s perspec-
tive. The analysis compared a standard treatment pathway (STP) (adalimumab, 
etanercept and palliative care) with a similar pathway initialized with tocilizumab 
(TCZ). Disease severity was reflected by Health Assessment Questionnaire (HAQ) 
scores. As primary efficacy outcomes, American College of Rheumatology (ACR) 
response rates were used. Patient characteristics (age, gender and baseline HAQ 
score) and TCZ efficacy data were derived from the ADACTA trial, whereas effi-
cacy data for the remaining DMARDs were derived from a network meta-analysis 
of each medication’s trial outcomes. A mapping model transformed HAQ scores 
into QALYs. Clinical practice standards were defined by an expert panel of Greek 
Rheumatologists. Costs for pharmaceuticals and resource unit costs were obtained 
from official (Social Insurance) price lists. A discount rate of 3% was used for both 
costs and QALYs. Results: Results indicate that a treatment sequence starting 
with TCZ yields 1.17 more QALYs (9.38 vs. 8.21) for an additional cost of € 33,145 
(€ 125,409 vs. € 92,264) compared to the STP. The Incremental Cost – Effectiveness 
Ratio (ICER) was 28,325.5€ /QALY gained. Sensitivity Analysis confirms robustness 
of findings below a threshold of € 45.000. ConClusions: The results of the analy-
sis suggest that TCZ as a first-line biologic drug can be a cost-effective treatment 
option for the management of active RA in patients intolerant or contraindicated 
to MTX.
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objeCtives: A systematic review was conducted to: 1) Identify economic evalu-
ations of therapies for rheumatoid arthritis (RA), and 2) assess and critique how 
sequential therapies were modelled and evaluated. Methods: Systematic 
searches of ten databases were undertaken to identify published economic evalua-
tions of disease modifying therapies for RA. Searches were undertaken in February 
2013, with no date restriction. Studies were included if they reported a full compar-
ative economic evaluation. Identified studies were appraised using the Drummond 
economic evaluation checklist. Data extracted included economic evaluation data, 
along with data relating to sequential treatments. Data on the modelling methods 
used were also extracted, to identify how data sources were synthesised. The 
systematic review was conducted to the PRISMA standards. Results: Fifty-seven 
studies were identified. 43 (75%) were cost-utility analyses. 11 (19%) had a UK 
perspective, and 11 (19%) had a US perspective. The remainder were mainly under-
taken within Europe (26 (46%) studies). There was a distinction between studies 
in recent-onset RA (14 (25%)), and those in established RA (42 (74%)). One study 
(1%) was unclear. The review identified approximately 30 RA treatments. Using 
individual level modelling was associated with improved quality of the evaluation 
and the ability to evaluate sequences. Reporting about the impact of future treat-
ments on costs and health benefits was poor. When downstream treatments were 
modelled, the evidence used was often poorly reported. No study considered iden-
tifying the optimal sequence of treatments given a set of alternative treatments. 
Where models have been developed that consider a lifelong time horizon and 
downstream treatment sequences, evidence gaps were identified. ConClusions: 
The review has identified that methods have not been consistently applied, which 
has led to varied estimates of cost-effectiveness. Sequences of treatments have 
not been appropriately considered and modelled, potentially biasing estimates 
of cost-effectiveness.
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objeCtives: Rheumatoid Arthritis (RA) is a chronic, inflammatory disease affecting 
0.68% of the adult population in Greece. RA is associated with a lowered quality of 
life and a serious economic burden. This study aims to evaluate the cost-effective-
ness of adding tocilizumab to a treatment sequence on a background of methotrex-
ate (MTX) for patients with active RA, who had an inadequate response to one or 
more traditional disease-modifying antirheumatic drugs (tDMARDs). Methods: A 
patient-level simulation model was applied to project lifetime costs and outcomes 
for 10.000 patients from a payer’s perspective. The analysis compared a standard 
treatment pathway (STP) (Adalimumab, Etanercept, Abatacept and Palliative care 
along with MTX) with a similar pathway initialized with Tocilizumab (TCZ). Disease 
severity was reflected by Health Assessment Questionnaire (HAQ) scores. As pri-
mary efficacy outcomes American College of Rheumatology (ACR) response rates 
were used . Patient characteristics (age, gender and baseline HAQ score) and drug 
efficacy for TCZ were obtained by an analysis of pooled data from three phase-III 
clinical trials. Efficacy data for comparators were derived from indirect compari-
sons. A mapping model transformed HAQ scores into QALYs. Standards regard-
ing clinical practice were defined by an expert panel of Greek Rheumatologists. 
Costs for pharmaceuticals and resource unit costs were derived from official (Social 
Insurance) price lists. A discount rate of 3% was used for costs and QALYs. Results: 
Results indicate that a treatment sequence starting with TCZ yields 0.79 more 
QALYs (11.68 vs. 10.89) for an additional cost of € 21,174 (€ 168,963 vs. € 147,788) 
compared to STP. The Incremental Cost – Effectiveness Ratio was 26,686€ /QALY 
gained. Sensitivity Analysis confirms robustness of findings below a threshold of 
€ 45.000. ConClusions: The results of the analysis suggest that TCZ, combined 
with MTX, as a first-line biologic drug can be a cost-effective treatment option for 
the management of active RA compared to STP.
thresholds (32,6% of the patients) required a DXA measurement to verify the diagnosis 
of osteoporosis. Cost-effectiveness was assessed in five patient cohorts: women (BMI 
24 kg/m2) aged 65 years with previous fracture and 75 or 85 years with and without 
previous fracture. Results: Among the cohorts modeled, the average screening cost 
saved with Bindex® including proposed pathway in comparison to current guideline 
pathway were around € 230/patient. At a cost of € 50/screen, the probability that the 
pathway including Bindex® was cost-effective compared to the current pathway was 
100% in all patient cohorts. Bindex® including pathway appeared to be cost-effective 
at prices as high as € 100/screen. ConClusions: Bindex® including pathway appears 
to be cost-saving strategy compared to the current and recommended Finnish osteo-
porosis diagnosis and care pathway.
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objeCtives: To evaluate the cost-effectiveness of Infliximab (IFX) treatment in severe, 
active paediatric ulcerative colitis (pUC). Methods: A Markov model was constructed 
based upon the literature, to model the progression of a cohort of pUC patients treated 
with IFX and ciclosporin (CIC) used off-label in the rescue therapy setting. The transi-
tion probabilities were estimated from the IFX phase III trials (T72, ACT1 and ACT2).
The comparative efficacy was incorporated by using the odds ratio for IFX vs. CIC from 
a head to head trial in adults (Laharie et al). Utility weights from observational studies 
(SOLUTION and Arseneau et al) were assigned to the health states within the Markov 
process. Incremental cost-effectiveness ratios (ICERs) were estimated with a one year 
time horizon. Uncertainty around key variables was explored through deterministic 
sensitivity analysis. Results: Compared to CIC in the rescue therapy setting, IFX 
was a dominant treatment option (produced more QALYs at a lower cost). The results 
were sensitive to the number of days patients were hospitalised for each treatment, 
the comparative rates of adverse events and altering the odds ratio for comparative 
effectiveness. ConClusions: IFX is a highly effective and well-tolerated therapy 
for the treatment of paediatric patients with severely active ulcerative colitis. IFX is 
the only biologic treatment licensed for this population, and is cost-effective when 
compared to the commonly used off-licence treatment CIC.
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objeCtives: Analyze Tocilizumab (TCZ) monotherapy cost-utility for moderate/ 
severe rheumatoid arthritis in patients who are intolerant/contraindicated to MTX, com-
pared with two standard treatment sequences: comparison 1: Etanercept-Adalimumab-
Certolizumab-Support treatment vs. Tocilizumab-Etanercept-Adalimumab-Support 
treatment, and comparison 2: Adalimumab-Etanercept-Certolizumab- Support treat-
ment vs. Tocilizumab-Adalimumab-Etanercept-Support treatment. Methods: A life 
time micro-simulation model with 6 months cycles was performed in order to 
calculate the incremental cost-effectiveness ratio of the TCZ treatment sequences 
vs. standards sequences, which were determined by an expert panel of Spanish 
rheumatologists. Demographic data on age, HAQ score and sex were obtained 
from the ADACTA trial, while body weight data was obtained from the PRAXIS 
study. The efficacy data (ACR clinical response) were obtained from the pivotal 
clinical trial of each drug. Utilities were calculated from the relationship between 
ACR response, HAQ score and EQ5D instrument, according to the VACAR study, 
conducted in the Spanish population. The analysis was done from National Health 
System (NHS) perspective. Unit costs (€ ; 2012) were obtained from Spanish sources. 
Annual discount rate was 3.5% for costs and outcomes. Probabilistic sensitivity 
analyses were performed. Results: TCZ sequences generated more costs per 
patient than the standard sequence (€ 7,107 in comparison 1; € 6,087 in comparison 
2). However, the TCZ sequence generated more QALYs than the standard sequence 
(0.330 in comparison 1 and 0.297 in comparison 2). The cost of gaining a QALY with 
TCZ sequences versus the standard sequence was € 21,529 (comparison 1) and € 
20,496 (comparison 2). According to probabilistic sensitivity analyses, the prob-
ability that the TCZ sequences are cost effective is 86.8% for the comparison 1 and 
86.1% for the comparison 2. ConClusions: In both comparisons, the analysis 
results indicate that the inclusion of TCZ monotherapy as first-line represents 
an effective and cost-effective alternative in Spain versus the current sequences 
used for the treatment of patients with rheumatoid arthritis and MTX intoler-
ance/contraindication.
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objeCtives: Rheumatoid Arthritis (RA) is a chronic, inflammatory disease 
affecting 0.68% of the adult population in Greece. RA is associated with a lowered 
quality of life and a serious economic burden. This study aims to evaluate the 
cost-effectiveness of adding tocilizumab to a treatment sequence for patients with 
active RA, who had an inadequate response to one or more traditional disease-
